Like Marijuana / Hemp Stocks? Check out our Marijuana / Hemp Stocks Directory for investors
Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing
Also check out our blog Global Cannabis Investing
CannaSOS is a comprehensive social network and advertising platform geared towards worldwide cannabis industry. CannaSOS is divided into multiple sections: Strain Database, Pulse, Advice, Business, Store, News, Social, all developed primarily to generate leads for businesses.
Since opening the doors to the public in January of 2014, CannaSOS acquired over 315,000+ registered members, 970+ active business pages, 4,900+ marijuana strain database, 200+ social groups, 8,500+ user strain reviews, over 3,900,000 strain page views, 2380 posted advice Q/A, 3700+ posted articles, and much more.Buy PerkCoins
SinglePoint, Inc. (OTCQB:SING) has grown from a full-service mobile technology provider to a publicly traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base. Through its subsidiary company SingleSeed the company is providing products and services to the cannabis industry. www.SinglePoint.comGet News Alerts on SinglePoint, Inc.
Viridian's Scott Greiper to Speak at NYC Bar Association Cannabis Seminar
RISE Life Science (CSE: RLSC) Announces the RISE Report: A Study to Explore Cannabis Use and Sexual Health
#Cannabis Stock News: Canntab (CSE: $PILL.C) Provides Corporate Update
SinglePoint (OTCQB: $SING) Continues Expansion into Cannabis Industry as Proposed Legislation Favors Industry Growth
Cannabis Stock Update: Let's Toke Business - Week of April 20th
MONQ Partners with Greenlane for Worldwide Distribution
Brigadier Gold (TSXV: $BRG-H.V) Announces Retention of #Cannabis Consultant; #420Day
New Federalism Fund and American Trade Association for Cannabis and Hemp Join Forces to Form New Industry Effort
420TV Celebrates 420 Day By Redefining The 'Typical Pot User'
VICE News - Sen. Chuck Schumer to introduce bill to "decriminalize" marijuana
|Estelle Fennell is named California Cannabis Authority president|
|Document: Parliament of Australia – Parliamentary Budget Office, “Tax & Regulate Cannabis”|
|Cannabis Business Times lists all the sponsors of the Marijuana Justice Act|
|Marijuana’s New Look In Los Angeles|
|Keystone ReLeaf vs State of Pennsylvania : Judgement|
|Canadian Market Projected Growth|
|Diagnosing Why Canada’s Medical Market Should Thrive|
|Canadian Market Projected Growth|
|New Green Rush in the Great White North|
|Something to Declare: Legalized Cannabis Leads to Fewer Border Interceptions|
To learn about subscribing email: firstname.lastname@example.org
22nd Century Group Inc. (NYSE MKT:XXII) is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company's primary mission is to reduce the harm caused by smoking. 22nd Century currently owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications around the world. The Company's strong IP position led to a licensing agreement with British American Tobacco ("BAT"), the world's second largest tobacco company.
3DX Industries Inc. (OTC: DDDX) is focused on the additive metal manufacturing segment within the manufacturing industry. 3DX has the capability of manufacturing a wide variety of products using its 3D metal printing system, 3D composite printing as well as more traditional methods of precision manufacturing. 3DX offers additive and subtractive manufacturing options as well as product design, engineering and assembly services to its customers. Cannabis: Has completed the development and design of a new and innovative product used for recovering excess heat from high energy grow lights. The part was designed specifically for the legalized cannabis markets including medical marijuana using the company's 3D Metal printing -- Binder Additive manufacturing process and is expected to be installed in select licensed facilities for real world testing in the coming months.
ABATTIS BIOCEUTICALS (OTC:ATTBF; CSE:ATT) is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions.
ABcann Global Corporation (TSX:ABCN.V) was one of the first companies to obtain a production license under the Marijuana for Medical Purposes Regulations, which it received on March 21, 2014. It obtained a sales license on December 31, 2015. ABcann's flagship facility, in Napanee, Ontario, contains proprietary plant-growing technology, including environmentally-controlled chambers capable of monitoring and regulating all variables in the growing process. This approach and the systems in place allow ABcann to produce organically grown and pesticide-free, high-yielding plants, which, in turn, can generate high-quality products that are consistent from batch to batch. ABcann is able to control environmental and nutrient demands, tailor-made for a particular strain of cannabis, without the variation that is typical when producing large quantities in less-controlled, larger rooms and greenhouse-type structures. ABcann's modular approach to systems technology eliminates scale-up risk and allows ABcann to locate anywhere in the world and maintain consistency and quality of product. ABcann is expanding capacity in its current facility to approximately 30,000 sq ft and concurrently undertaking expansion into a new 150,000 sq ft facility in Napanee. ABcann is pursuing opportunities in Germany, Australia and other jurisdictions as well as exploring the development of multiple delivery vehicles.
Acology Inc (OTC:ACOL) markets and sells the TSOS Container™ (The Science of Storage).This container is the first-ever FDA approved polypropylene air-tight, water-tight, smell-proof delivery and storage container with a built-in grinder. It is manufactured from medical-grade No. 5 polypropylene resin, which is non-porous and non-leaching. These containers are portable and affordable. he Medtainer™ allows patients to store, grind and pour a variety of medications, including pills and all sizes and solidity, herbal medications and teas and even coffee and spices! The Medtainer™ can be ordered in with a certified child-resistant cap. Each Medtainer™ is water-proof and smell proof. Caregivers who are responsible for ensuring their patients medication regimens are universally pleased with the how easy and effective the Medtainer™ grind medications. It is an excellent solution for patients with dysphasia due to cognitive disorders or brain injuries, are in hospice or palliative situations and for anyone who would rather not swallow whole pills. The MedTainer™ was originally developed for geriatric and pediatric patients who had difficulty swallowing pills or needed an effective alternative to costly name-brand medications. The MedTainer™ has been sold and is being successfully used throughout the United States, Canada, Mexico and South America and Europe. Our association with the Medical Marijuana community was an unexpected windfall that has given Acology, Inc. the necessary funding to expand into the growing hospice and palliative care markets, and to help countless patients who are living at home or in small home-like settings and need help swallowing pills.
Advantis Corp (OTC:ADVT) develops products and works with developing companies to provide innovative healthcare products, holistic pain management solutions, and enhance the footprint in the evolving legal cannabis business. Advantis acquires ownership in developing companies that work within the nutraceutical and the alternative health care industries; consulting with these organizations to improve their product lines, expand their distribution channels through internal partnership agreements, and heighten brand value.
Aequus Pharmaceuticals Inc. (TSX:AQS.V) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus' development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. Cannabis: July 2017 - Aequus Pharmaceuticals Inc., ("Aequus") (TSX VENTURE: AQS) (OTCQB: AQSZF), a specialty life sciences company focused on providing patients with differentiated and enhanced delivery systems for existing and approved drugs, and Scientus Pharma Inc., ("Scientus"), a biopharmaceutical company focused on R&D and product commercialization for extracts and formulations related to medical cannabinoids and their derivatives, announced today that they have signed a non-binding term sheet on a collaboration to develop, assess clinical performance, and commercialize a cannabinoid containing transdermal formulation designed and optimized to address both acute and chronic treatment of Resistant Epilepsy, and certain other neurological disorders. Scientus will be the supplier of specific cannabinoid extracts and will have an option to co-fund the clinical development of this program. The parties expect to expand the collaboration to additional product development programs in the future.See the full stock directory here